Profile: Eli Lilly and Co (LLY)
26 Jul 2016
Eli Lilly and Company, incorporated on January 17, 1901, is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. Its products are sold in over 120 countries. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and over 10 other countries.
Human Pharmaceutical Products
The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products and cardiovascular products. The Company's endocrinology products include Humalog, Humalog Mix 75/25 and Humalog Mix 50/50, which are insulin analogs for the treatment of diabetes; Humulin, which is a human insulin of recombinant deoxyribonucleic acid (DNA) origin for the treatment of diabetes; Trajenta, which is used for the treatment of type II diabetes; Jentadueto, which is a combination tablet of linagliptin (Trajenta) and metformin hydrochloride for use in the treatment of type II diabetes; Jardiance, which is used for the treatment of type II diabetes; Trulicity, which is used for the treatment of type II diabetes; Glyxambi, which is a combination tablet of linagliptin and empagliflozin (Jardiance) for the treatment of type II diabetes; Synjardy, which is a combination tablet of empagliflozin and metformin hydrochloride for the treatment of type II diabetes; Basaglar (insulin glargine injection), which is a long-acting human insulin analog for the treatment of diabetes; Forteo, which is used for the treatment of osteoporosis in postmenopausal women and men at risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women; Evista, which is used for the prevention and treatment of osteoporosis in postmenopausal women and for managing the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at risk for invasive breast cancer; Humatrope, which is used for the treatment of human growth hormone deficiency and certain pediatric growth conditions, and Axiron, which is a topical solution of testosterone, applied by underarm applicator, for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone.
The Company's neuroscience products include Cymbalta, Zyprexa, Strattera, Prozac and Amyvid. Cymbalta is used for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain due to chronic low back pain or chronic pain due to osteoarthritis. Zyprexa is used for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder and bipolar maintenance. Strattera is used for the treatment of attention-deficit hyperactivity disorder. Prozac is used for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa and panic disorder. Amyvid is a radioactive diagnostic agent, which is used for positron emission tomography imaging of beta-amyloid neuritic plaques in the brains of adult patients with cognitive impairment, who are being evaluated for Alzheimer's disease and other causes of cognitive decline.
The Company's oncology products include Alimta, Erbitux, Cyramza, Gemzar and Portrazza. Its product, Alimta, is used for the first-line treatment, in combination with another agent, of non-small cell lung cancer (NSCLC) for patients with non-squamous cell histology; for the second-line treatment of non-squamous NSCLC; as monotherapy for the maintenance treatment of non-squamous NSCLC in patients, and in combination with another agent, for the treatment of malignant pleural mesothelioma. Erbitux is indicated both as a single agent and with another chemotherapy agent for the treatment of certain types of colorectal cancers. It is used as a single agent, in combination with chemotherapy, or in combination with radiation therapy for the treatment of certain types of head and neck cancers. Gemzar is used for the treatment of pancreatic cancer; in combination with other agents, for the treatment of metastatic breast cancer, NSCLC, advanced or recurrent ovarian cancer, and in the European Union for the treatment of bladder cancer. Cyramza is approved in the United States and the European Union both as a single agent and in combination with another agent for advanced or metastatic gastric cancer, and approved in the United States in combination with another agent as a second-line treatment of metastatic NSCLC. Portrazza is approved in the United States for use in combination with other agents as a first-line treatment of metastatic squamous NSCLC, and approved in the European Union for use in combination with other agents as a first-line treatment for epidermal growth factor receptor expressing squamous NSCLC.
The Company's cardiovascular products include Cialis, Effient and ReoPro. Cialis is used for the treatment of erectile dysfunction and benign prostatic hyperplasia. Effient is used for managing thrombotic cardiovascular events in patients with acute coronary syndrome, including patients undergoing angioplasty, atherectomy or stent placement. ReoPro is used as an adjunct to percutaneous coronary intervention (PCI) for the prevention of cardiac ischemic complications.
Animal Health Products
The Company's animal health products segment includes products for food animals, products for companion animals and Novartis Animal Health (Novartis AH) products. The Company's products for food animals include Rumensin, which is a cattle feed additive that manages coccidiosis; Posilac, which is a protein supplement to manage milk productivity in dairy cows; Paylean and Optaflexx; Tylan, which is an antibiotic used to control certain diseases in cattle, swine and poultry; Micotil, Pulmotil and Pulmotil AC, antibiotics used to treat respiratory disease in cattle, swine and poultry; Coban, Monteban, and Maxiban, which are anticoccidial agents for use in poultry, Surmax (sold as Maxus in various countries), and Imrestor, which is a biopharmaceutical that restores neutrophil function in peri-parturient dairy cows.
The Company's products for companion animals include Trifexis, Comfortis, Onsior, Interceptor Plus and Osurnia. Trifexis is a monthly chewable tablet for dogs that kills fleas, manages flea infestations, prevents heartworm disease and controls intestinal parasite infections. Comfortis is a chewable tablet that kills fleas and manages flea infestations on dogs. Onsior is a non-steroidal short-term pain reliever for cats administered orally or by injection. Interceptor Plus is a canine heartworm drug that fights tapeworms in addition to hookworms, roundworms and whipworms. Osurnia is a gel formulation treatment for canine ear canal infection or inflammation.
The Company's Novartis AH products include Denagard, Milbemax, Sentinel, Atopica and Fortekor. Denagard is an antibiotic for the control and treatment of respiratory and enteric diseases in swine and poultry. Sentinel is a monthly tablet for the prevention of flea populations, the concurrent prevention of heartworm disease and the treatment of roundworms, hookworms, and whipworms in dogs. Atopica is used for the treatment of chronic manifestations of atopic dermatitis in dogs and for the symptomatic treatment of chronic allergic dermatitis in cats. Fortekor is used for the treatment of congestive heart failure in dogs and can manage proteinurea associated with chronic kidney disease in cats.
Eli Lilly and Co
Lilly Corporate Ctr, Drop Code 1
INDIANAPOLIS IN 46285
Company Web Links
- Lilly sales beat estimates, helped by newer drugs
- BRIEF-Eli Lilly CEO John Lechleiter says view a future where drug pricing is going to be challenging across the board- CNBC
- BRIEF-Eli Lilly reports quarterly earnings of $0.71 per share
- Lilly quarterly profit, sales jump on demand for new drugs
- Fitch Affirms Eli Lilly's IDR at 'A'; Outlook Stable